Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Feb 12, 2016. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q4 2015. Go to the latest filing (Q3 2026)

5.5B USDQ4 2015
Total value of stock positions
5.5B USD
Positions
34
Share of the ten largest
78.7%

The ten largest positions Q4 2015

  1. Cheniere Energy Inc 17.7%▲ +15.1%
  2. E M C Corp Mass 13.7%new
  3. Viasat Inc 12.8%unchanged
  4. Antero Res Corp 7.6%▲ +19.1%
  5. Pbf Energy Inc 7.4%unchanged
  6. PayPal 7.3%▲ +1.9%
  7. Theravance Inc 3.8%unchanged
  8. Twenty First Centy Fox Inc 3.2%unchanged
  9. Atara Biotherapeutics Inc 2.6%unchanged
  10. Keryx Biopharmaceuticals Inc 2.4%unchanged
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q4 2015

Positions Q4 2015 per 13F filing, 34 of 34
Symbol Weight Shares Reported value Change Held since
Cheniere Energy Inc 17.7% 26,089,669 971.8M USD +15.1% increased Q1 2014 8 quarters
E M C Corp Mass 13.7% 29,248,619 751.1M USD new Q4 2015 1 quarter
Viasat Inc 12.8% 11,533,137 703.6M USD unchanged Q2 2013 or earlier 11 quarters
Antero Res Corp 7.6% 19,167,944 417.9M USD +19.1% increased Q3 2014 6 quarters
Pbf Energy Inc 7.4% 11,025,000 405.8M USD unchanged Q3 2013 10 quarters
PYPL PayPal 7.3% 11,109,278 402.2M USD +1.9% increased Q3 2015 2 quarters
Theravance Inc 3.8% 19,815,983 208.9M USD unchanged Q2 2013 or earlier 11 quarters
Twenty First Centy Fox Inc 3.2% 6,527,500 177.7M USD unchanged Q3 2015 2 quarters
Atara Biotherapeutics Inc 2.6% 5,359,632 141.5M USD unchanged Q4 2014 5 quarters
Keryx Biopharmaceuticals Inc 2.4% 25,791,678 130.2M USD unchanged Q1 2014 8 quarters
Olin Corp 2.2% 7,000,000 120.8M USD unchanged Q3 2015 2 quarters
Twenty First Centy Fox Inc 2.0% 4,097,500 111.3M USD unchanged Q3 2015 2 quarters
Theravance Biopharma Inc 1.9% 6,420,028 105.2M USD unchanged Q2 2014 7 quarters
Veritiv Corp 1.9% 2,885,682 104.5M USD +3.2% increased Q3 2014 6 quarters
Forward Pharma A/S 1.9% 5,367,300 102.0M USD unchanged Q4 2014 5 quarters
Novagold Res Inc 1.5% 18,977,449 79.9M USD −12.5% reduced Q2 2013 or earlier 11 quarters
Chipmos Tech Bermuda Ltd 1.4% 3,751,853 74.3M USD unchanged Q2 2013 or earlier 11 quarters
Sunedison Semiconductor Ltd 1.2% 8,372,979 65.6M USD unchanged Q2 2014 7 quarters
Klx Inc 1.1% 2,000,000 61.6M USD +33.3% increased Q1 2015 4 quarters
Frontier Communications Corp 0.9% 10,915,236 51.0M USD −19.1% reduced Q2 2015 3 quarters
Ocwen Finl Corp 0.7% 5,200,427 36.2M USD unchanged Q3 2014 6 quarters
RUN Sunrun 0.6% 2,848,082 33.5M USD +143.2% increased Q3 2015 2 quarters
American Intl Group Inc 0.5% 1,258,496 29.9M USD unchanged Q2 2013 or earlier 11 quarters
Frontier Communications Corp 0.5% 325,000 29.8M USD unchanged Q2 2015 3 quarters
Paratek Pharmaceuticals Inc 0.5% 1,544,498 29.3M USD unchanged Q4 2014 5 quarters
Bellatrix Exploration Ltd 0.5% 23,990,500 29.0M USD unchanged Q4 2014 5 quarters
Kosmos Energy Ltd 0.4% 4,618,796 24.0M USD −23.0% reduced Q2 2014 7 quarters
Biotie Therapies Oyj 0.4% 1,395,000 20.0M USD +11.1% increased Q2 2015 3 quarters
Citigroup Inc 0.3% 102,553,207 18.5M USD unchanged Q2 2013 or earlier 11 quarters
MU Micron Technology 0.3% 1,000,000 14.2M USD unchanged Q2 2013 or earlier 11 quarters
Kindred Biosciences Inc 0.2% 3,013,848 10.2M USD unchanged Q4 2013 9 quarters
Sanchez Energy Corp 0.2% 2,000,000 8.6M USD +100.0% increased Q2 2015 3 quarters
Orexigen Therapeutics Inc < 0.1% 2,268,399 3.9M USD +176.2% increased Q3 2015 2 quarters
Novacopper Inc < 0.1% 10,600,758 3.0M USD unchanged Q2 2013 or earlier 11 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 1 position in convertible bonds and bonds worth 36.1M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Inc principal 48.2M USD 36.1M USD

Breakdown by sector

  • Financials 7.3%
  • Industrials 0.6%
  • Technology 0.3%
  • not in our coverage 91.8%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close